TransCode Therapeutics, Inc. (RNAZ) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
6 Liberty Square
Boston, MA 02109
United States of America (the)
Phone
857-837-3099
Sector
Healthcare
Industry
Biotechnology
Employees
7
First IPO Date
July 08, 2021
| Name | Title | Pay | Year Born |
| Philippe Calais | Chief Executive Officer & Executive Chairman of the Board | 566,116 | 1959 |
| Thomas A. Fitzgerald | Chief Financial Officer, President, Vice President of Administration & Director | 1.07M | 1952 |
| Zdravka Medarova | Scientific Co-Founder & Chief Scientific Officer | 0 | 1975 |
| Anna Moore | Scientific Co-Founder, Scientific Advisor & Chair of Scientific Advisory Board | 0 | 1962 |
| Susan Duggan | Senior Vice President of Operations | 0 | N/A |
| Daniel R. Vlock | Chief Medical Officer | 0 | 1952 |
TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers. Beyond its primary candidate, the company's preclinical portfolio also features TTX-siPDL1, an siRNA designed to modulate programmed death-ligand 1, and TTX-siLIN28B, another siRNA that inhibits the RNA-binding protein LIN28B. TransCode also pursues several cancer-agnostic initiatives. These encompass TTX-RIGA, an RNA-based agent engineered to stimulate the RIG-I immune pathway within the tumor's immediate surroundings; TTX-CRISPR, a gene-editing platform utilizing CRISPR/Cas9 technology to correct or eradicate oncogenic genes within cancer cells; and TTX-mRNA, an innovative mRNA platform dedicated to creating cancer vaccines that incite powerful cytotoxic immune reactions against malignant cells. Established in 2016, TransCode Therapeutics is headquartered in Boston, Massachusetts.